CRISPR Therapeutics AG
CRSP- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001674416
In the last 90 days, CRISPR Therapeutics AG insiders filed 0 open-market purchases and 2 sales; 525 institutions reported holding it in 13F filings for Q2 2026, worth $4.16B in total; ARK Invest is the only superinvestor holding it.
Q4 2025 vs. Q3 2025
How the institutions holding CRISPR Therapeutics AG changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 442 | 4 | 482 | +44 |
| Shares | 72.2M | 9.21K | 76.5M | +4.26M (+5.9%) |
| Value | $4.68B | $598.1K | $4.01B | −$669.3M (−14.3%) |
4 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (96)
Institutions that held CRISPR Therapeutics AG at the end of Q4 2025 but not at the end of Q3 2025.
Sold out (52)
Institutions that held CRISPR Therapeutics AG at the end of Q3 2025 and filed for Q4 2025 without it.
Not filed for Q4 2025 yet (4)
Institutions that held CRISPR Therapeutics AG at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| CIBC Bancorp USA Inc. | 8,824 | $571.9K |
| AllSquare Wealth Management LLC | 253 | $16.4K |
| Accredited Wealth Management, LLC | 129 | $9.72K |
| Guerra Advisors Inc | 1 | $65 |